• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Fate Therapeutics, Inc. (FATE)

    6.86 Up 0.17(2.54%) Jul 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Fate Therapeutics, Inc.
    3535 General Atomics Court
    Suite 200
    San Diego, CA 92121
    United States - Map
    Phone: 858-875-1800
    Website: http://www.fatetherapeutics.com

    Index Membership:N/A
    Full Time Employees:50

    Business Summary 

    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular therapeutics for the treatment of severe, life-threatening diseases. It has a platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. The company focuses primarily on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system. The company’s lead product candidate is ProHema, an ex vivo programmed hematopoietic cellular therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies in adults; in Phase Ib clinical development for hematologic malignancies in pediatric patients; and in Phase Ib clinical development for inherited metabolic disorders in pediatric patients. It is also developing a triple modulator combination of pharmacologic modulators that programs human CD34+ cells to express high levels of PD-L1, a key immunosuppressive protein; and in vivo therapeutic potential of PD-L1 programmed CD34+ cells to selectively home to sites of, and suppress, T cell proliferation, and cytokine production. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Fate Therapeutics, Inc.

    Key Executives 
    Dr. Christian Weyer M.D., M.A.S., 45
    Chief Exec. Officer, Pres and Director
    Mr. J. Scott Wolchko , 45
    Chief Operating Officer and Chief Financial Officer
    Dr. Michael Rudnicki Ph.D.,
    Dr. Daniel D. Shoemaker Ph.D., 47
    Chief Scientific Officer
    Ms. Cindy R. Tahl J.D.,
    VP of Intellectual Property and Sr. Corp. Counsel
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders